Here are the 10-K annual reports from Edwards Lifesciences Corp (EW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EW filings page.
Edwards Lifesciences outlines its 2025 business, emphasizing leadership in structural heart therapies. Transcatheter Aortic Valve Replacement (TAVR) remains the core franchise, representing 74% of 2025 net sales, while Transcatheter Mitral and Tricuspid Therapies contributed 9% and Surgical Structural Heart valves 17%.
The company reports an aggregate market value of common stock held by non‑affiliates of $45,899,189,298 as of June 30, 2025, with 580.8 million shares outstanding as of January 31, 2026. Research and development spending rose about 2% and reached roughly 18% of 2025 sales, reflecting heavy investment in next‑generation TAVR, TMTT and surgical platforms.
Edwards generated 58% of net sales in the United States and 42% internationally, operates in about 100 countries, and employed roughly 16,000 people as of December 31, 2025. The filing details extensive risk factors, including innovation and clinical trial execution, manufacturing quality, competition from Medtronic and Abbott, reimbursement pressure, global regulatory change, cybersecurity, AI governance, and tax and compliance exposure.